Trial Profile

Open-label study to evaluate the safety, tolerability, and efficacy of LOmitapide for the treatment of patients with Familial CHylomicroNEmia Syndrome

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 28 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lomitapide (Primary)
Indications Hyperlipoproteinaemia type I
Focus Therapeutic Use
Acronyms LOCHNES

Most Recent Events

01 Oct 2022 Results evaluating the efficacy and safety of lomitapide in adult patients with FCS, published in the Atherosclerosis
30 Mar 2021 According to an Amryt Pharma media release, this study was conducted by expert lipidologists in Italy. The company will now evaluate and analyse the full data set from the study.
30 Mar 2021 Results published in the Amryt Pharma Media Release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com